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Complimentary DNAs for three beta-adrenergic receptors (βARs) were isolated and 27 
characterised in the fathead minnow. The encoded proteins of 402 (β1AR), 397 (β2AR) and 28 
434 (β3AR) amino acids were homologous to other vertebrate βARs, and displayed the 29 
characteristic seven transmembrane helices of G Protein-coupled receptors. Motifs and amino 30 
acids shown to be important for ligand binding were conserved in the fathead minnow 31 
receptors. Quantitative RT-PCR revealed the expression of all receptors to be highest in the 32 
heart and lowest in the ovary. However, the β1AR was the predominant subtype in the heart 33 
(70%), and β3AR the predominant subtype in the ovary (53%). In the brain, β1AR expression 34 
was about 200-fold higher than that of β2- and β3AR, whereas in the liver, β2AR expression 35 
was about 20-fold and 100-fold higher than β3- and β1
 45 
AR expression, respectively. Receptor 36 
gene expression was modulated by exposure to propranolol (0.001 – 1 mg/L) for 21 days, but 37 
not in a consistent, concentration-related manner. These results show that the fathead minnow 38 
has a beta-adrenergic receptor repertoire similar to that of mammals, with the molecular 39 
signatures required for ligand binding. An exogenous ligand, the beta-blocker propranolol, is 40 
able to alter the expression profile of these receptors, although the functional relevance of 41 
such changes remains to be determined. Characterisation of the molecular targets for beta-42 
blockers in fish will aid informed environmental risk assessments of these drugs, which are 43 
known to be present in the aquatic environment.    44 
 46 
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1. Introduction 51 
Adrenergic receptors (ARs) belong to the G protein-coupled receptor (GPCR) superfamily of 52 
proteins, which constitute the largest proportion of membrane signal transducers [38]. There 53 
are two main types of adrenoceptors, the αARs and βARs, and for each several subtypes have 54 
been identified in mammals: α1a, α1b, α1d, α2a, α2b, α2c, and β1, β2, β3 [13, 59]. There is 55 
emerging evidence that fish also express the same receptors; for example, α1a-, α1b-, α1d ARs 56 
have been characterised in rainbow trout [10]; α2b-, α2c- and α2d ARs in zebrafish [54]; β1-, 57 
β2- and β3 ARs in zebrafish [67] and black bullhead [16]; β2- and β3
 62 
AR in rainbow trout [41, 58 
42]. Additionally, genomic sequencing has identified homologues in medaka, stickleback, 59 
fugu and tetraodon, and a search of GeneBank reveals several partial sequences of teleost 60 
adrenoceptors.  61 
The function of the adrenergic receptor system is believed to be the same in fish as it is in 63 
mammals, with activation of signal transduction following epinephrine/norepinephrine 64 
binding [19]. The recent high-resolution structural studies [11, 44, 46, 68] have provided 65 
experimental confirmation of the predicted molecular mechanism of GPCR activation in 66 
general, and of adrenoceptors in particular (reviewed by Rosenbaum et al., [52]). Our 67 
increased understanding of the structural requirements for receptor interaction and activation 68 
is useful when assessing the likelihood of receptors in other species becoming targets for 69 
agonists and antagonists designed for human receptors.  70 
 71 
Our interest is the potential effects on aquatic organisms, especially fish, of pharmaceuticals 72 
present in the aquatic environment. Currently, approximately 150 different drugs have been 73 
detected in rivers and waterways [53] and there is concern that some of these, particularly 74 
those which have a high usage, are potent at low concentrations, poorly degraded or with a 75 
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propensity for bioaccumulation, may pose a threat to aquatic organisms [30, 61].   For 76 
example, ethinylestradiol, a component of the contraceptive pill, has been found to be a 77 
highly potent endocrine disrupter in fish at low environmental concentrations [8]. The beta-78 
adrenoceptor blockers (β-blockers) are a group of pharmaceuticals widely prescribed for 79 
conditions such as high blood pressure, cardiac arrhythmias, glaucoma, anxiety and 80 
migraines, which exert their effects by binding to βARs and thereby preventing the 81 
interaction of epinephrine with its receptors. They are present in the aquatic environment at 82 
concentrations ranging from < 0.8 to 2900 ng/L [62, 65], and from acute EC50 data it appears 83 
that atenolol is non-toxic, whilst metoprolol would be classified as toxic and propranolol as 84 
very toxic to aquatic organisms [14].  Chronic data with respect to aquatic life and β-blockers 85 
are scarce, but recent studies indicate that these human drugs may affect fish at 86 
concentrations below toxic levels [43, 69]. This suggests the presence of βARs, and we report 87 
here the characterisation of three beta-adrenoceptors, β1, β2 and β3
 95 
, in the fathead minnow. 88 
The receptors contain the conserved amino acids and motifs identified as being important for 89 
agonist and antagonist binding, and receptor activation. Gene expression data also suggests 90 
that similar physiological effects to those seen in mammals may be expected following ligand 91 
binding, and modulation of receptor expression was seen following chronic exposure to 92 
propranolol. However, the functional importance of such changes requires information at the 93 
protein level, and remains to be determined. 94 
2 Materials and Methods 96 
2.1   Tissue acquisition   97 
Fathead minnows, Pimephales promelas, were bred and maintained at Brunel University as 98 
detailed in Giltrow et al. [25]. Liver tissue was used for the characterisation of βARs, whilst 99 
receptor expression analysis was performed on liver, brain, heart and ovary tissue from 100 
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female fish. We also examined receptor expression in these tissues obtained from fathead 101 
minnows exposed to different concentrations of propranolol (0.001, 0.01, 0.1 and 1 mg/L) for 102 
21 days [25].  The tissues were immediately snap frozen in liquid nitrogen after removal and 103 
stored at -80 °C until use.   104 
 105 
2.2 Identification of βARs  106 
Total RNA was extracted from liver using 1 ml of TriReagent (Sigma, Dorset, UK) for every 107 
50 to 100 mg of tissue. The RNA quality was verified using 1.2 % agarose gel electrophoresis 108 
and quantified on a Nanodrop ND-1000 spectrophotometer.  mRNA was isolated using 109 
Genelute mRNA miniprep kit (Sigma, Dorset, UK) and complementary DNA (cDNA) was 110 
obtained using Superscript III reagents and protocol (Invitrogen, Paisley, UK).   111 
The oligonucleotide primers and annealing temperatures used in obtaining putative β1AR, 112 
β2AR and β3AR fragments are shown in Table 1.  AmpliTaq Gold (Applied Biosystems, 113 
Warrington, UK) was used in all PCR reactions.  Putative βAR fragments were cloned, 114 
sequenced and localised to a particular βAR using Blast searches (www.ncbi.nlm.nih.gov).  115 
Rapid Amplification of cDNA Ends PCR (RACE PCR; Invitrogen, Paisley, UK and 116 
Clontech, California, USA) was used to obtain the remainder of the sequence in each 117 
direction.  The complete receptor sequences were amplified using primers designed to the 3’ 118 
and 5’ untranslated regions (UTRs) and proof reading Taq (Pwo SuperYield DNA 119 
polymerase, Roche, Sussex, UK).  Following cloning, the receptor sequences were confirmed 120 
by ‘primer walking’ in each direction in triplicate (Dundee University’s Sequencing Service, 121 
www.dnaseq.co.uk).   122 
 123 
2.3   Characterisation of βAR sequences 124 
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The fathead minnow βAR sequences were used to search for homologues in other species 125 
using Blast (www.ncbi.nlm.nih.gov). Sequence and phylogenetic analyses were performed 126 
using the following database entries: For β1AR: Homo sapiens (human) NP_000675, Danio 127 
rerio (zebrafish) NP_001122161, Takifugu rubripes (fugu) ENSTRUP00000031392, 128 
Gasterosteus aculeatus (stickleback) ENSGACP00000008698, Oryzias latipes (medaka) 129 
ENSORLP00000006043, Ovis aries (sheep) AAB34523,  Mus musculus (mouse) 130 
NP_031445, Xenopus laevis (frog) NP_001084152, Meleagris gallopavo (turkey) 131 
AAA49627; For β2AR: Human AAA88015, zebrafish adrb2a NP_001096122, zebrafish 132 
adrb2b BAH84779, Oncorhynchus mykiss (rainbow trout) NP_001117912, Tetraodon 133 
nigroviridis (tetraodon) ENSTNIP00000020193, fugu AAQ02695, stickleback 134 
ENSGACP00000024398, medaka ENSORLP00000009383, sheep NP_001123626, mouse 135 
NP_031446, frog NP_001085791, Ciona intestinalis (ciona) XP_002121940;  For β3AR: 136 
Human NP_000016, zebrafish adrb3a BAH84778, zebrafish adrb3b NP_001128606, rainbow 137 
trout adrb3a NP_001118100, rainbow trout adrb3b NP_001117924,  Ameiurus melas (black 138 
bullhead) adrb3b ABH10580, stickleback ENSGACP00000014582, fugu 139 
ENSTRUP00000020757, medaka ENSORLP00000014229, sheep AAG31167, mouse 140 
NP_038490;  For β4cAR
 142 
: Salmo salar (salmon) NP_001133926, turkey AAA62150. 141 
The positions of seven transmembrane helices were predicted using the hydropathy analysis 143 
programme TM_PRED (http://www.ch.embnet.org/software/TMPRED_form.html), and 144 
refined by manual comparisons to the crystal structures of bovine rhodopsin [44], turkey 145 
β1AR [46] and human β2AR [11, 68] in order to more accurately predict the length of the 146 
helices, as structural analysis had revealed these to extend further into the cytoplasm than 147 
suggested by hydropathy-based computer modelling. Prediction of palmitoylation sites was 148 
carried out using CSS-Palm 2.0 [47]. Potential phosphorylation of serine, threonine and 149 
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tyrosine residues in the intracellular loop 3 and cytoplasmic tail was identified using NetPhos 150 
2.0, and protein kinase phosphorylation sites were predicted using NetPhosK 1.0 151 
(http://www.cbs.dtu.dk/services/NetPhos) [6].  152 
 153 
2. 4 Phylogenetic analysis   154 
The βAR amino acid sequences were aligned using ClustalW (2.0.3), and the phylogenetic 155 
tree created using the Neigbourhood-Joining algorithm with 1000 bootstrap replicates in 156 
ClustalX (2.0.12) [36]. The un-rooted tree was visualised using Dendroscope V2.7.4 157 
(www.dendroscope.org), and rooted with Ciona intestinalis β2
 159 
AR as the outgroup.  158 
2.5  Gene Expression 160 
The expression of β1AR, β2AR and β3AR in liver, brain, ovary and heart of female fathead 161 
minnows was quantified using real-time PCR (QPCR). Primers were as follows: β1AR 162 
(185bp) forward 5’CTTCGTATTTTTGAACTGGC3’, reverse 163 
5’CCATTGAGTTCACAAAGCCC3’; β2AR (224bp) forward 164 
5’AGGTGATCAAGAGTCGAGTG3’, reverse 5’ATGCTAATTAAGACCACCTC3’; β3AR 165 
(105bp) forward 5’GGCCCAGCAAAAAACATCC3’, reverse 166 
5’TTCCCATAGTGCTTGCCTCCTC3’.  The amplicons were cloned and sequenced to 167 
confirm their identities. QPCR standard βARs were prepared by in vitro transcribing cloned 168 
amplicons to generate RNA (Riboprobe, Promega), which was serially diluted (107-101 169 
molecules) prior to use.  Assays (20 µl) utilising Quantitect SYBR Green (Qiagen) and 0.5 170 
µM (β1AR and β2AR) or 0.1 µM (β3AR) each of forward and reverse primers were carried 171 
out in 96-well plates, with an efficiency greater than 90%. One µl of each sample mRNA (5 172 
ng/µl), RNA standards and non-template control (sterile water) were assayed in triplicate. 173 
The QPCR cycling included a reverse transcription step (30 min at 50 oC, 15 min at 95 oC), 174 
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followed by 40 cycles of amplification (15 sec each at 95 oC, 55 oC and 72 oC for β1AR; 15 175 
sec each at 95 oC, 56 oC and 72 oC for β2AR; 30 sec each at 95 oC, 55 oC and 72 oC for 176 
β3AR), and elongation for 15 min at 72 o
 181 
C. There was no significant difference between the 177 
threshold cycle (Ct) value for each RNA standard concentration between assay plates, and 178 
absolute gene expression was calculated from the standard curves and plotted as copies/ng 179 
mRNA.  180 
3  Results 182 
3.1   Sequence Analysis 183 
The fathead minnow βAR sequences have GenBank accession numbers GQ901985 (β1AR), 184 
GQ901986 (β2AR) and GQ901987 (β3AR).   Fathead minnow cDNA sequences for β1AR 185 
(1413 bp), β2AR (1437 bp) and β3
Blast searches showed fathead minnow β
AR (2203 bp) were found to code for proteins of 407, 397 186 
and 434 amino acids, respectively (Fig. 1), which is comparable to the size of βARs in other 187 
species.   188 
1AR and β2AR to be most homologous to zebrafish 189 
β1AR and β2bAR, respectively, with scores of 88% and 86% homology.  Subsequent matches 190 
in these searches were to other fish and mammal β1AR o r β2ARs.  The fathead minnow 191 
β3AR was found to be most homologous to zebrafish β3aAR (74% homology), followed by 192 
other fish β3AR and salmon β4cAR receptors (around 60%).  Identities to the human βARs 193 
are 51%, 55% and 40% for β1AR, β2AR and β3AR, respectively. Comparison of the three 194 
fathead minnow receptors gave a homology of 51% between β1AR and β2AR, whereas β3AR 195 
was 45% and 41% identical to β1AR and β2
 197 
AR, respectively.  196 
3.2  Topology and motifs 198 
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The positions and amino acid sequences of the seven transmembrane (TM) domains (Fig. 1) 199 
are highly conserved between different species; for example, fathead minnow and turkey 200 
β1ARs have an average sequence identity of 79% (range 59-88%) in the TM regions 201 
compared to 57% over the whole sequence, and fathead minnow and human β2
 206 
AR have an 202 
average identity of 74% (range 57-86%) in the TMs compared to 58% overall. The TMs are 203 
also conserved between receptor types, and between the three fathead minnow βARs there is 204 
53% identity in the TM regions compared to 31% overall.  205 
In addition to the seven transmembrane helices, characteristic of all GPCRs, the fathead 207 
minnow βARs share motifs associated with the Family A (rhodopsin) receptors (Fig. 1). This 208 
family of GPCRs are characterised by a series of highly conserved residues in the TMs: 209 
Asn1.50 in helix 1, Asp2.50 in helix 2, Arg3.50 in helix 3, Trp4.50 in helix 4, Pro5.50 in helix 5, 210 
Pro6.50 in helix 6 and Pro7.50 in helix 7 [23]. These fingerprint residues are numbered 211 
according to the Ballesteros-Weinstein numbering scheme, where the most conserved residue 212 
in each helix is given the number 50 in order to facilitate comparisons between different 213 
receptors [4], and all are present in the fathead minnow βARs. Most family A receptors also 214 
contain a disulfide bond connecting the beginning of TM3 and the second extracellular loop 215 
[23, 68], and in the fathead receptors this is proposed to be formed by Cys3.25 and Cys202 216 
(β1), Cys194 (β2) or Cys182 (β3). The fathead minnow β1AR Cys195-Cys201 and β2AR 217 
Cys187-Cys193 are also likely to form an additional intra-loop disulfide bond in extracellular 218 
loop 2 [68], which is not present in β3AR.  Like most Family A receptors [23], the fathead 219 
minnow βARs are predicted to contain a palmitoylated cysteine in the carboxy-terminal tail 220 
at positions Cys 347 (β1AR), Cys340 (β2AR) and Cys349 (β3AR).  The amino-terminal 221 
region of the receptors has potential N-glycosylation sites (Asn-X-Ser/Thr), with three 222 
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possible sites in β1AR and β2AR. The β3
 225 
AR has one potential site in this region, but also has 223 
the potential for glycosylation of extracellular loop 2 on Asn173.     224 
Prediction of putative phosphorylation sites in the fathead minnow βARs revealed there to be 226 
5, 6 and 10 potential Ser and Thr sites in the carboxy-terminal end of the β1AR, β2AR and 227 
β3AR, respectively. Additionally, intracellular loop 3 contained 2, 2 and 4 sites. Kinase 228 
binding prediction suggested possible interaction with a range of kinases in all three 229 
receptors, with highest scores obtained for protein kinase C in intracellular loop 3 of β1AR 230 
(Thr266) and β3AR (Ser263), and protein kinase B with Ser247 of β2AR. In the carboxy-231 




3.3  Phylogenetic analysis 235 
The phylogenetic analysis (Fig. 2) clearly differentiates the three beta-adrenergic receptor 236 
subtypes. The fathead minnow and zebrafish are both members of the Cyprinidae family [66], 237 
and this close evolutionary relationship is reflected in the grouping of their receptors. 238 
Interestingly, the salmon β4cAR showed close relatedness to the trout β3bAR receptor, and 239 
pair-wise alignment revealed these to be 97 % identical. It is therefore highly likely that the 240 
salmon receptor is a β3 subtype, and we propose it should be re-named accordingly. Turkey 241 
β4cAR is grouped with the human, mouse and sheep β3ARs, but this receptor has been fully 242 
characterised and shown to differ from the human β3
 245 
AR pharmacologically as well as 243 
structurally [9].   244 
3.4 Gene expression  246 
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Fathead minnow βARs were expressed in all tissues examined (Fig. 3), with highest 247 
expression observed in the heart (2,000-65,000 copies/ng mRNA) and lowest in the ovary 248 
(45-160 copies/ng mRNA). In the brain, expression of β AR was about 200-fold higher than 249 
that of β2- and β3AR, whilst in the liver the β2AR was expressed about 20-fold and 100-fold 250 
higher than β3AR and β1AR, respectively. The expression of β3AR showed the least 251 
variation in the tissues examined, with only about a 20-fold difference between lowest (102 252 
copies/ng mRNA in brain and ovary) and highest (2x103 copies/ng mRNA in the heart) 253 
expression. In contrast, β2AR expression varied about 350-fold between brain (<102 254 
copies/ng mRNA) and heart (2x104 copies/ng mRNA), and β1AR 1400-fold between ovary 255 
(<102 copies/ng mRNA) and heart (6x104
 257 
 copies/ng mRNA).   256 
Exposure of fathead minnows to propranolol for 21 days altered β1-, β2- and β3
 261 
AR 258 
expression in the different tissues, but not in a consistent, concentration-related manner (Fig. 259 
4).  260 
4 Discussion 262 
We report here the characterisation of β1-, β2- and β3ARs in the fathead minnow. The 263 
sequence comparisons and phylogenetic analyses provide unambiguous evidence that the 264 
three receptors represent different AR subtypes; the sequence identity between the three 265 
receptors range from 41% (β1AR vs β3AR) to 51% (β1AR vs β2AR), and they are located in 266 
different clades in the phylogenetic tree (Fig. 2). Comparison with the recently reported 267 
zebrafish receptors [67] shows that the fathead minnow β2 receptor is most similar to the 268 
β2bAR subtype (86% identity vs. 57% to the zebrafish β2aAR), and the fathead minnow β3 269 
receptor is most similar to the β3aAR (74% identity vs. 46% to zebrafish β3bAR). However, 270 
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we were unsuccessful in obtaining other full-length β2- and β3ARs from fathead minnow 271 
liver, and therefore believe it is inappropriate to refer to the receptors reported here as a 272 
particular β2- or β3AR subtype. The presence of multiple copies of genes in teleost fish 273 
would be expected, as three whole genome duplications (3R) are believed to have taken place 274 
since the origin of vertebrates some 500 to 800 million years ago [21]. However, subsequent 275 
gene loss has also occurred, and therefore there is uncertainty as to the number of gene 276 
subtypes present in a single species. In a study designed to determine the number of βAR 277 
genes in zebrafish [67], a single β1AR and two β2- and β3AR genes were found. Given the 278 
close relatedness between zebrafish and the fathead minnow, it is likely that there may be 279 
further β2- and β3ARs encoded by the fathead minnow genome yet to be identified.   280 
Phylogenetic analysis of 136 adrenoceptor sequences suggests that the βARs diverged 0.86-281 
0.37 billion years ago [3], and the chronogram presented by these authors implies that β2AR 282 
may have given rise to the β1- and β3ARs. In contrast, our analysis suggests β1- and β2ARs 283 
to have evolved from a β3AR, but this may be a function of the outgroup used (Ciona 284 
intesinalis β2
 286 
AR) and the reduced number of sequences included in this analysis.   285 
The fathead minnow receptors display the characteristic seven transmembrane helices of 287 
GPCRs, and contain the conserved amino acid residues and motifs considered important for 288 
ligand binding and activation.  3-D structural studies of human β2AR and turkey β1AR [46, 289 
68] have helped identify residues important for receptor activation and signal transduction. 290 
All three fathead minnow βARs have the amino acid residues believed to be important for 291 
binding epinephrine in a human β2AR [20], where interaction with the ligand occurs by the 292 
formation of a salt bridge with Asp3.32, by hydrogen bonding with Ser5.42, Ser5.43, Ser5.46 and 293 
Asn6.55, and hydrophobic interactions with Ile4.61 and Phe6.52 (Ballesteros-Weinstein 294 
numbering). All fathead minnow receptors also contain Asn7.39, critical for the interaction 295 
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with antagonists such as propranolol [35], and Val3.33, which by mutational analysis has been 296 
shown to affect agonist and antagonist binding to hamster β2AR [2].  The conserved DRY 297 
motif in TM3 is thought to have a role in stabilising the inactive receptor conformation 298 
through interaction with Glu6.30 in TM6 [52], thereby maintaining a low constitutive activity 299 
in the absence of ligand. The NPXXY motif at the end of TM7 is also believed to be 300 
important in maintaining an inactive state through forming a water pocket network of 301 
hydrogen bonds [52].  A further conserved residue, Trp6.48
 309 
, has been named the “rotamer 302 
toggle switch” [57], due to its conformational transition required for GPCR activation. 303 
Conservation of the important ligand binding residues suggests that the fathead minnow 304 
receptors can interact with the same ligands as human βARs, including beta-blockers.  This 305 
conclusion is supported by Ruuskanen et al. [54], who found that ligand binding 306 
characteristics, the order of potency and efficacy of tested agonists were all highly conserved 307 
between zebrafish and human αARs. 308 
Regulation of GPCRs, including the β-adrenergic receptor response, is primarily by 310 
phosphorylation of serine or threonine residues in the third intracellular loop and C-terminal 311 
tail by a broad range of protein kinases and G-protein coupled receptor kinases (GRK) [63]. 312 
This leads to receptor desensitisation, arrestin recruitment and receptor internalisation, 313 
effectively terminating the signalling response. Previous studies of trout [41] and black 314 
bullhead β2ARs [16] indicated that fewer potential phosphorylation sites were present in fish 315 
than in mammals, and this is believed to explain the apparent absence [15, 22] or reduced 316 
effectiveness [16] of receptor desensitisation observed in physiological studies. The fathead 317 
minnow β3AR has a greater number of potential phosphorylation sites than predicted for β1- 318 
and β2AR, as appears to also be the case for the black bullhead receptors [16]. However, the 319 
significance of this is not known. Recent studies (reviewed by [32, 63]) have suggested that 320 
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the number of phospho-serine and phospho-threonine residues may not be the decisive factor 321 
in controlling GPCR signalling, as the extent of phosphorylation is not necessarily related to 322 
the affinity for arrestins, or subsequent internalisation. New roles for arrestins have also been 323 
discovered, whereby the internalised receptor-arrestin complex acts as a scaffold to facilitate 324 
protein-protein interactions, leading to activation of MAPK signalling cascades [45] and 325 
acting as a signal initiator rather than signal terminator. It is therefore clear that the regulation 326 
of the βARs may be complex, and further studies are required to elucidate the importance of 327 
the proposed phosphorylation sites.        328 
 329 
The fathead minnow βARs were expressed in all tissues tested, with highest expression 330 
observed in the heart. There is general agreement that it is the β1AR subtype which is of 331 
greatest functional importance in the heart [49], and similar to mammals the fathead minnow 332 
β1AR receptors constitute 70% of the total βARs present in that tissue. The β1AR is also the 333 
predominant subtype in zebrafish heart [67], and functional studies have shown that the heart 334 
rate of zebrafish [56] and medaka [31] can be modulated by isoproterenol (agonist) and 335 
propranolol (antagonist). Although these agents are not β1AR specific [60], they would be 336 
anticipated to interact with the predominant βAR receptor present, and indeed adrb1 337 
morpholino knock-downs resulted in reduced heart rate [67].  β3AR constitute only 2% of the 338 
fathead minnow heart adrenoceptors, and although β3AR actions have been identified in 339 
rodent atria [58] and eel hearts [29] using isolated preparations, their physiological relevance 340 
in the presence of a much larger number of β1ARs is not known. However, β3
 344 
ARs could 341 
have particular importance in specific areas of the heart, although in the human heart at least, 342 
this remains controversial [37].  343 
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Our study also indicates that β1AR is the predominant receptor subtype (99%) in the fathead 345 
minnow brain, in agreement with the high expression level seen in the brains of zebrafish 346 
[67] and mammals [26].  The low expression of fathead minnow β2AR in brain is similar to 347 
the expression reported for the zebrafish β2bAR, whereas the β2aAR was highly expressed in 348 
this tissue [67]. It is therefore likely that the distribution of β2AR in zebrafish brain reported 349 
by Ampatzis and Dermon [1] reflects the localisation of the β2aAR subtype. The role of βARs 350 
in the brain is likely to be diverse. For example, it has been suggested that activation of brain 351 
βARs could have a role in energy metabolism, increasing glycogenolysis and Na+/K+
 355 
-ATPase 352 
activity in mice [27], and in mediating norepinephrine-modulated memory formation in the 353 
chick [24]. 354 
In fathead minnow liver, the predominant receptor subtype is β2AR (95%), which agrees 356 
with the expression seen for zebrafish β2bAR [67], rainbow trout [41] and mammal β2
 360 
AR 357 
[48]. The metabolism of glucose and free fatty acids in liver is therefore likely to be mediated 358 
via activation of this receptor [64]. 359 
Whilst there is general agreement with regards to tissue localisation of β1AR and β2ARs in 361 
fish, differing localisation of β3AR has been reported. In fathead minnow, the β3AR was 362 
detected in heart>liver>ovary>brain (this study), and additionally we have found it to be 363 
present in the gill, red blood cell and adipose tissue (unpublished data). We therefore cannot 364 
rule out that some of the β3AR expression, especially in highly vascularised tissues such as 365 
the heart and liver, is accounted for by residual blood in those tissues. Both zebrafish β3ARs, 366 
similar to trout β3bAR, were expressed predominantly in the blood with very low expression 367 
in other tissues [42, 67], whereas black bullhead β3bAR was present in the liver [16], and 368 
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trout β3aAR in heart, gill and red muscle [42]. The picture is further confused by the fact that 369 
the trout β3ARs share 84% sequence identity and are more similar to zebrafish β3a- than β3b 370 
receptors. The apparent broad tissue distribution of fish β3AR is similar to mammals, where 371 
β3 receptors have been found to be present not only in adipose tissue, but also in liver, 372 
muscle [17] gallbladder, colon [34], brain [50], stomach, prostate [5] and oocytes [12], with 373 
the possibility of wide-ranging actions.  Interestingly, whilst expression levels in the fathead 374 
minnow ovary were low, the β3AR was the predominant adrenoceptor (53%) in that tissue. A 375 
specific role for the β3
 379 
AR in the human myometrium has been suggested by a study showing 376 
that it is the predominant βAR subtype in that tissue, and it is upregulated in near-term 377 
pregnant myometrium [51]. 378 
Exposure to propranolol, a non-selective beta-blocker, altered expression of the three βARs 380 
to different extents in the fathead minnow tissues tested, and whilst some significant up- and 381 
down-regulation (compared to control fish) were observed, there were no consistent dose-382 
response effects. The lack of a concentration-related response is particularly interesting given 383 
that at the highest (0.1 and 1 mg/L), but not the lower (0.001 and 0.01 mg/L) doses, plasma 384 
propranolol levels in the fish exceeded human therapeutic levels [25]. Studies in man and rats 385 
are conflicting, but suggest that chronic treatment with beta-blockers can up-regulate receptor 386 
density [7], although there appears to be no direct relationship between receptor gene 387 
expression and protein levels [28, 39]. However, it should be noted that the human data is 388 
generally obtained from studies of people with severe cardiac problems, and the response 389 
may therefore not be comparable to our study with healthy fish. Thus, whilst it appears that 390 
chronic exposure to propranolol can modulate βAR gene expression in fathead minnow 391 
tissues, the results need to be replicated and include receptor protein measurements and 392 




In summary, we have shown the presence of three beta adrenergic receptor subtypes (β1, β2, 395 
β3) in the fathead minnow. The conserved amino acid residues and motifs important for 396 
agonist and antagonist binding are present, and tissue localisation of the receptors is similar 397 
to that observed in humans.  It is therefore likely that pharmaceuticals targeting these 398 
receptors could cause effects if present in the aquatic environment, but further work is 399 
required to determine if such effects are detrimental at environmental
 411 
 concentrations. Our 400 
studies to date would suggest levels would need to reach mg/L concentrations; acute toxicity 401 
has only been observed at very high exposure concentrations of atenolol (>10 mg/L) [69] and 402 
propranolol (>3 mg/L) [25], and reproductive effects at 1 mg/L propranolol [25]. We also 403 
have an indication that beta-adrenergic receptor specific actions, such as the effect of 404 
propranolol on heart rate, require exposure to mg/L concentrations [41]. Although the 405 
environmental concentration of propranolol is generally in the ng/L range, levels as high as 406 
6.5 µg/L have been reported in hospital effluents in Spain [55]. The latter is still an order of 407 
magnitude below where effects have been observed, suggesting that, in general, propranolol 408 
will not constitute an environmental hazard. However, the propensity for propranolol to 409 
bioaccumulate [18, 25] indicates that, in some specific locations, it could be of concern. 410 
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Figure Legends 614 
 615 
Figure 1. Alignment (Clustal 2.2.10) of fathead minnow β1-, β2- and β3
 625 
AR amino acid 616 
sequences. Transmembrane helices (TM1-TM7) are indicated below the alignment. Light 617 
grey boxes indicate putative N-linked glycosylation sites. Residues in squares are those 618 
highly conserved throughout the rhodopsin family of GPCRs. Cysteines involved in disulfide 619 
bonding are shown in green. Ligand binding residues (red) and motifs important in stabilising 620 
the inactive receptor (light blue) are shown. The “rotamer toggle switch” is shown in yellow.  621 
The palmitoylation site is shown in dark blue. Potential phosphorylation sites (dark grey) are 622 
indicated.   (*) Indicates identical amino acid sequence in that column, (:) shows conserved 623 
substitutions have been made and (.) indicates that semi-conserved substitutions are observed. 624 
Figure 2.  Phylogenetic tree constructed using the neighbour-joining algorithm, with Ciona 626 
intestinalis β2AR as the outgroup. The node numbers refer to bootstrap values after 1000 627 
iterations. The β1- (adrb1), β2- (adrb2) and β3
 631 
 adrenergic receptors (adrb3) are present in 628 
different clades, and the fathead minnow βARs are grouped with the respective zebrafish 629 
receptors.  630 
Figure 3.   mRNA expression of β1-, β2- and β3
 637 
 adrenergic receptors in female fathead 632 
minnow tissues. Using RNA standards, absolute levels of expression was determined and   633 
data is presented as number of copies/ng mRNA +/-SEM. Three replicates of each sample 634 
were analysed; n=7-8 for liver, ovary and brain, whereas the small size of the heart required 635 
these to be pooled and as a consequence n=1.    636 
27 
 
Figure 4.   mRNA expression of β1-, β2- and β3 adrenergic receptors in female fathead 638 
minnow tissues obtained from fish exposed to different concentrations of propranolol (0, 639 
0.001, 0.01, 0.1 and 1 mg/L) for 21 days. Propranolol concentrations were measured and 640 
found to be similar to nominal values [25]. Using RNA standards, absolute levels of 641 
expression was determined and data is presented as number of copies/ng mRNA +/-SEM. 642 
Three replicates of each sample were analysed; n=7-8 for liver, ovary and brain, whereas the 643 
small size of the heart required these to be pooled and as a consequence n=1.     644 
Table 1. Gene specific primers used for amplification of fragments and complete sequences of the β1-, β2- and β3
Receptor 
ARs in the Fathead Minnow  
 
Forward Primer Reverse Primer Annealing  
Temperature ⁰C a 

















67.0, 66.0, 65.0 
70.6, 68.5, 65.0 
67.5, 66.0, 65.0 
β1-AR 5’ RACEb    5’ATCAAGAGATATCCAGAATTCACAGAAGAACGA 67.0, 65.0, 60.0 3’ 
β1-AR whole sequence 5’GAGAGCGCGGATGGAAG3’ 5’GGAAATATTTTCGAATTTGTCTGAAACG 58.9 3’ 






β2-AR  3’ RACEb
(nested reactions) 









69.5, 67.0, 65.0 
69.0,67.0, 65.0 
69.0, 67.0, 65.0 
β2-AR  5’ RACEb
(nested reactions) 











β2-AR whole sequence 5’CGACATTTAGTCTACAGCCGAGAGTG3’ 5’ACATCTAAAAACCATGTTTTGTCACAGAC 54.0 3’ 























β3-AR 3’ RACEb GSP1:    5’TTCAATCGAGATCTGCTAACC  3’ 68.0 
(nested reactions) GSP2:  5’ CAGAGTTTCGTGCGGCCTT 68.0 3’ 
β3-AR 5’ RACEb
(nested reactions) 






β3-AR whole sequence 5’CACGCTGACTGAACCTCCTCC3’ 5’CCGGGCTGAAGTGGATTGCTCCAGTAC 70.0 3’ 
 
aThe three temperatures denotes those used for cycles 1-5 cycles, cycles 6-10 and cycles 11- 30, respectively. bFor 3’ and 5’ RACE the reverse 
and forward primers were those provided by the manufacturer. 
 β1AR           MEALHTGPEVLNERASFLHTMGDGLPSVNYSNDSKRTPDNLSEQWLVGMGIIMGLVVIVI 60 
β2AR           ---MEGGDRLSVENTSLHMNVSSGL------NDSS-PVSEYSDAEVVLISILMGLLVLGI 50 
β3AR           --------MESLTNSS---------------QTTPVPTSAPLQGWTSFQLFIMIIIIAII 37 
                            .:*               : :  . .   :       ::* :::  * 
                                                           ----------TM1--- 
 
β1AR           VVGNILVIVAIARNQRLQTLTNVFIVSLACADLIMGLLVVPFGADLEVRGSWMYGSFFCE 120 
β2AR           VFGNVLVISAIVRFQRLQTGTNYFISSLACADLVMGLMVVPFGACYILLNTWHFGNFFCE 110 
β3AR           VVGNLMVIIAIARTSQLQTTTNIFIMSLACADLIMGVVVVPLAAMIVVKGEWTLGEVPCR 97 
               *.**::** **.* .:*** ** ** *******:**::***:.*   : . *  *.. *. 
               -------------       -------------TM2-------------      ----- 
 
β1AR           FWISLDVLCVTASIETLCVIAIDRYIAITSPFRYQSLLTKARAKVVVCAVWAISALVSFP 180 
β2AR           FWTATDVLCVTASIETLCVIALDRYVAIMWPLRYQSMLTKRKACGIVLAVWAVAALISFL 170 
β3AR           LWTSVDVLCVTASIETLCINAVDRYIAIMRPLRYKVLLNKCRARIIVCVVWLLSALISFV 157 
               :* : *************: *:***:**  *:**: :*.* :*  :* .** ::**:** 
               ----------TM3----------------          -------------TM4----- 
 
β1AR           PILMHWSR--DTVDTS-CYNEPECCDFITNREYAISSSVISFYIPLIVMIFVYARVYREA 237 
β2AR           PIHMEWWVSDDPDALS-CLKNPTCCDFNTNAAYAVTSSIVSFYIPLVIMVFVYSRVFQEA 229 
β3AR           PIMNDWHAGADTGNKNDTDNYKDTCAFDTNMAFAIFSSGISFYIPLLIMIFVYARVFLVA 217 
               **  .*    *.   .   :    * * **  :*: ** :******::*:***:**:  * 
               ---                           -----------------TM5---------- 
 
β1AR           KQQLKKINKCEGRFYNN--GTNCKPN--------------------RKRTTKILALKEQK 275 
β2AR           RRQLQKIDRIEGRIRTQSFSTQDGNE--------------------TKNRRTKFGMKDHK 269 
β3AR           TRQVQLIGNNRLRFQNECIGNQVHGNNNLPSMCNNVGGMTARRKSSRRRPSKLTAVKEHK 277 
                :*:: *.. . *: .:  ..:   :                     :.  .  .:*::* 
        -                                                        --- 
 
β1AR           ALKTLGIIMGTFTLCWLPFFIVNVVRVFGKEVVKKELFVFLNWLGYVNSAFNPIIYCRSP 335 
β2AR           ALKTLGIIMGTFTLCWLPFFVLNVAAAIWKMENIMLPFRILNWIGYANSAFNPLIYCRSP 329 
β3AR           ALKTLGIIMGIFTLCWLPFFVANIINVFNRDLLTMYVFRYLNWLGYINSSLNPIIYCRSP 337 
               ********** *********: *:  .: :       *  ***:** **::**:****** 
               --------TM6-----------------      ----------TM7-------- 
 
β1AR           DFRKAFKRLLCCPRQADRRLHVSSCDLSRCTGGFVNSMEQSMLGTWSDCNGTDSRDCSLE 388 
β2AR           EFRCAFQEILCR-----RTSHLPS---TRNNKGFIYSGHSWKVHTKTARQREPSPACETE 374 
β3AR           EFRAAFKNLLGCPWVSPLRMNFLYKELRTRCTCFLGSAESGMPGSFEKPPTSPGALPGEG 397 
               :** **:.:*          :.           *: * ..    :                
 
β1AR           RNGRVSHSESQL--------------------------407 
β2AR           MGAGNGNCNKAVTSDF----------------------397 
β3AR           SSQSSYRSEEPSPGPPHSNGRTFFSDFSEPETEFCNL 434 
                                 
 
 
 
 
 
Figure 1. 
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